Combined BRAF-MEK inhibition for advanced BRAF-mutant melanoma led to significantly better progression-free survival (PFS) as compared with single-agent BRAF inhibition, according to a randomized trial.
2023
Melanoma Linked to Altered Gut Microbes in Case-Control Study
In a paper appearing in JAMA Dermatology, investigators at the University of Texas MD Anderson
Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLC
Nicholas Coupe, MBBS, PhD, oncologist, Oxford University Hospitals, NHS Foundation Trust, discusses the rationale for investigating IMM60 with pembrolizumab (Keytruda) in patients with advanced melanoma or metastatic non-small cell lung cancer (NSCLC), as well as key background information that led to this investigation.
Q&A: Advances in surgery are improving survival for people with melanoma
The National Cancer Institute estimates that 97,610 people will be diagnosed with melanoma in 2023, making up 5% of all new cancer diagnoses. Fortunately, screening and treatment have improved, allowing care teams to catch melanoma earlier when it’s easier to treat. As a result, the number of people who survive the disease has steadily increased.